Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eliquis, Orencia sales propel Bristol-Myers to strong second quarter

07/25/2019 | 01:27pm EDT
Logo of global biopharmaceutical company Bristol-Myers Squibb is pictured on the blouse of an employee in Le Passage

NEW YORK (Reuters) - Bristol-Myers Squibb Co, which is set to buy biotechnology company Celgene Corp for $74 billion, posted better-than-expected second-quarter profit on Thursday on strong sales of blood thinner Eliquis and rheumatoid arthritis treatment Orencia.

Shares of the New York-based drugmaker were up 4.8% at $45.30 in afternoon trading.

The earnings follow mixed results released on Wednesday from a closely watched lung cancer trial of its blockbuster immunotherapy Opdivo in combination with either chemotherapy or its other immuno-oncology drug, Yervoy.

"While some of the drug data was disappointing, there was enough positivity for the combination of Opdivo and Yervoy that would suggest there is potential for that to gain share for a longer period of time," said Jeremy Bryan, portfolio manager at Gradient Investments.

Sales of Eliquis, which Bristol-Myers shares with Pfizer Inc, rose 24% to $2.04 billion, while Orencia sales rose 9% to $778 million, both exceeding Wall Street expectations.

Opdivo sales rose 12% to $1.82 billion.

Despite the solid growth for Opdivo, there has been widespread investor concern over the dominance of rival drug Keytruda from Merck & Co in the lucrative lung cancer market. Keytruda has surpassed Opdivo in sales in recent quarters and the company said it expects additional pressure on Opdivo sales next year.

The latest lung cancer data is unlikely to allay those concerns.

Opdivo combined with chemotherapy failed to extend overall survival more than chemotherapy alone as an initial treatment for advanced non-squamous non-small cell lung cancer (NSCLC). Keytruda plus chemotherapy has demonstrated a survival benefit in clinical trials.

Opdivo did extend overall survival when used with Yervoy in certain NSCLC patients.

Some analysts and investors have suggested that one reason Bristol launched its bid for Celgene was over concerns about Opdivo losing ground to Keytruda.

Bristol said it still expects the Celgene deal to close in late 2019 or early 2020.

Excluding one-time items, the drugmaker said it earned $1.18 a share for the quarter, beating analysts' expectations by 11 cents, according to IBES data from Refinitiv.

Bristol-Myers increased its full-year profit forecast by 10 cents and now expects to earn $4.20 to $4.30 a share.

Revenue in the quarter was $6.27 billion, topping Wall Street expectations of $6.11 billion.

The company reported a net profit of $1.43 billion, or 87 cents a share, compared with $373 million, or 23 cents a share, a year earlier.

(Reporting by Michael Erman, Additional reporting by Manas Mishra in Bengaluru; Editing by Cynthia Osterman, Susan Thomas and Bill Berkrot)

By Michael Erman


ę Reuters 2019
Stocks mentioned in the article
ChangeLast1st jan.
BRISTOL-MYERS SQUIBB COMPANY -0.30% 67.49 Delayed Quote.9.12%
CELGENE 0.10% 108.24 End-of-day quote.68.89%
MERCK & CO., INC. 0.79% 77.85 Delayed Quote.-5.57%
PFIZER, INC. 0.69% 42.1 Delayed Quote.13.58%
All news about BRISTOL-MYERS SQUIBB COMPANY
10:04aBRIDGEBIO PHARMA : Bristol Myers Squibb to Evaluate BBP-398 Combined With Opdivo..
MT
07/23BRISTOL MYERS SQUIBB : Statement on Opdivo« (nivolumab) Monotherapy Post-Sorafen..
PU
07/19PORTAGE BIOTECH CEO INTERVIEW EXPLAI : Prtg)
AQ
07/19COMPUGEN : Doses First Patient in Expansion Arm of Study Evaluating Triple Combi..
MT
07/19BRISTOL MYERS SQUIBB : MPN Hub continues to enhance global knowledge of myelopro..
AQ
07/19AML Hub continues to enhance global knowledge of acute myeloid leukemia throu..
AQ
07/16BRISTOL MYERS SQUIBB : Says Study of Opdivo Plus Yervoy Against Carcinoma Did No..
MT
07/16Bristol Myers Squibb Cancer Drug Study Falls Short of Endpoints
DJ
07/16BRISTOL MYERS SQUIBB : Provides Update on CheckMate -651 Trial Evaluating Opdivo..
BU
07/16Bristol-Myers Squibb Company Provides Update on Checkmate -651 Trial Evaluati..
CI
More news
Financials (USD)
Sales 2021 46 031 M - -
Net income 2021 7 797 M - -
Net Debt 2021 28 265 M - -
P/E ratio 2021 19,9x
Yield 2021 2,87%
Capitalization 151 B 151 B -
EV / Sales 2021 3,90x
EV / Sales 2022 3,47x
Nbr of Employees 30 250
Free-Float 76,3%
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | BMY | US1101221083 | MarketScreener
Technical analysis trends BRISTOL-MYERS SQUIBB COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 67,69 $
Average target price 75,18 $
Spread / Average Target 11,1%
EPS Revisions
Managers and Directors
Giovanni Caforio Chairman & Chief Executive Officer
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer & Executive VP
Rupert J. Vessey Executive VP-Research & Early Development
Joseph E. Eid Senior VP & Head-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BRISTOL-MYERS SQUIBB COMPANY9.12%151 141
JOHNSON & JOHNSON9.21%452 602
ROCHE HOLDING AG11.50%327 852
PFIZER, INC.13.58%234 040
NOVARTIS AG-0.17%221 954
ELI LILLY AND COMPANY44.05%221 084